Speakers
IZBrunch – Science meets Science: Theranostics: The See-and-Treat Revolution in Oncology

Theranostics is redefining cancer care. By combining targeted diagnostics with precision radiotherapy, tumors can now be detected and treated with unprecedented accuracy—turning nuclear medicine into a true “see and treat” approach. What was once a vision is rapidly becoming a global clinical reality. This IZBrunch explores the breakthrough therapies driving this transformation—and the challenge of making them accessible to patients worldwide.

Susanne Simon
Head of Communications & Community – ICPO Foundation
Topic: Scaling global patient access to Theranostics
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Together with partners worldwide, the ICPO Foundation is on a mission to establish an international network of certified ICPO Centers of Excellence by sharing knowledge and standards in Theranostics.
Aiming at sustainable patient access growth at each center, the ICPO Foundation has developed the ICPO Academy for Theranostics, a world-class online education platform dedicated to healthcare professionals active in Theranostics. Moreover, the ICPO Foundation supports young talents via research grants and nurtures a strong collaborative community, also by organizing its own virtual and in-person Events– advancing the field of Theranostics and listening to the patient voice.

Prof. Dr. Rudolf A. Werner
Director of the Clinic and Polyclinic for Nuclear Medicine – LMU University Hospital
Topic: Theranostics as a Novel Pillar in Oncology
Diagnostic radiotracers can identify target structures on the tumor cell surface, which is then followed by the use of slightly modified therapeutic radiopharmaceuticals. In recent years, such a theranostic approach (as a combination of “therapy” and “diagnostics”) has been included in the treatment algorithm of different tumor entities, including prostate or neuroendocrine cancers of the gastrointestinal region. After introducing this innovative “see-and-treat” concept, this talk will then give an overview on theranostic “block-busters” in clinical routine and provide a forecast on novel emerging targets, thereby highlighting how theranostics has the potential to re-shape the oncology landscape in the future.
Your Host

Christian Gnam
Managing Directo